Abstract
Pancreatic ductal adenocarcinoma (PDAC) is traditionally treated by a surgery-first approach. The development and adoption of the concept of borderline resectable PDAC, which extends the role of surgery, is based on the proposition that neoadjuvant therapy (NAT) will increase the resection rate, margin negative rate and overall survival. There are a number of issues with this concept and a critical review of these suggests that it is based on limited foundations and likely has a limited future.
| Original language | English |
|---|---|
| Pages (from-to) | 189-193 |
| Number of pages | 5 |
| Journal | Journal of Gastrointestinal Oncology |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2017 |
